
John Pinion has over 26 years of experience in biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas.
He joined Ultragenyx in July 2015 and is the executive vice president of translational sciences and chief quality operations officer. He provides leadership for Ultragenyx's translational sciences functions which includes pharmacology and toxicology, research and bioanalytical development, as well as GxP quality and compliance, CMC analytical development and QC.
In the ten years prior to joining Ultragenyx, Mr Pinion held roles of increasing responsibility at Genentech (subsequently Roche post Genentech acquisition), and 17 years in operational and senior leadership roles in Baxter International.